The significant revenue decline and increased net loss outweigh the positive developments in subsidiary capital raises and engineering services growth. Traders should be cautious about the company's ability to replace lost revenue and achieve profitability despite management's optimistic outlook for 2026.
Price Chart
Executive Summary
BioLargo reported its 2025 annual results, showing a significant revenue decline from $17.8M to $7.8M due to the loss of its largest customer's license, despite a 98% increase in engineering services revenue. The company reported a net loss of $15.2M (up from $4.3M in 2024) but maintains $3.9M in cash. The filing highlights commercial progress in its Clyra Medical and Cellinity Battery divisions, which both raised capital in 2025.
Key Facts
- Revenues for 2025 were $7,765,000, down from $17,779,000 in 2024
- Net loss in 2025 was $15,189,000, up from $4,347,000 in 2024
- Engineering services revenue increased 98% from $1,017,000 to $1,998,000
- Company lost its largest customer's license
- Cash balance at year-end was $3,883,000
- Clyra Medical and Cellinity Battery divisions raised capital in 2025
Financial Impact
Revenue declined 56% YoY from $17.8M to $7.8M, net loss increased 250% from $4.3M to $15.2M
Risk Factors
- Dependence on a single large customer that was lost
- Continued negative net income trend
- Unproven commercialization of new business segments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-007044 |
| Exhibit: ex_929178.htm | 0001437749-26-007044 |
| Document: 0001437749-26-007044-index-headers.html | 0001437749-26-007044 |
| Document: 0001437749-26-007044-index.html | 0001437749-26-007044 |
| Document: 0001437749-26-007044.txt | 0001437749-26-007044 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.0700 | awaiting T+60 | — | $0.0700 (−0.00%) |
Sep 11, 2026 6w ago | 8-K | $0.1000 | awaiting T+60 | — | $0.0700 (−30.00%) |
May 4, 2026 25w ago | 8-K | $0.1600 $0.1117 | ▼ −30.19% | ▼ −32.04% | $0.0700 (−56.25%) |
Apr 17, 2026 27w ago | 424B4 | $0.1500 $0.1120 | ▲ +25.33% | ▲ +32.11% | $0.0700 (+53.33%) |
Apr 17, 2026 27w ago | 424B4 | $0.1500 $0.1120 | ▲ +25.33% | ▲ +32.11% | $0.0700 (+53.33%) |
Mar 5, 2026 33w ago | 8-K | $0.1700 $0.1200 | ▲ +29.41% | ▲ +40.71% | $0.0700 (+58.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers